Feasibility of Using Endometrial Regenerative Cells in Multiple Sclerosis Treatment
Author Information
Author(s): Zhong Zhaohui, Patel Amit N, Ichim Thomas E, Riordan Neil H, Wang Hao, Min Wei-Ping, Woods Erik J, Reid Michael, Mansilla Eduardo, Marin Gustavo H, Drago Hugo, Murphy Michael P, Minev Boris
Primary Institution: The Second Xiangya Hospital, Central South University, Changsha, PR China
Hypothesis
Can allogeneic endometrial regenerative cells (ERC) be safely administered to patients with multiple sclerosis?
Conclusion
The study suggests that ERC can be administered safely without immediate immunological reactions or adverse effects in patients with multiple sclerosis.
Supporting Evidence
- ERC are immune privileged and can suppress immune responses.
- No immunological reactions or treatment-associated adverse effects were observed in the patients.
- The longest follow-up of a patient was over one year without adverse effects.
Takeaway
Doctors tried a new type of stem cell therapy on four patients with multiple sclerosis, and it seemed to be safe without causing any bad reactions.
Methodology
Four patients with multiple sclerosis were treated with allogeneic endometrial regenerative cells through intravenous and intrathecal administration under a compassionate use program.
Limitations
The study had a small sample size and limited number of injections.
Participant Demographics
All patients had multiple sclerosis and had failed standard treatment options.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website